Youjia Bio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Youjia Bio - overview
Established
2019
Location
Hangzhou, Zhejiang, China
Primary Industry
Biotechnology
About
Established in 2019 and based in Hangzhou, China, Youjia (Hangzhou) Biomedical Technology Co. , Ltd is a biomedicine company that focuses on research and development of nucleic acid drug. In 2022, the company raised an undisclosed amount of series A+ funding led by new investor Shanxi Growth Enterprise Leading Fund. The company's self-developed nucleic acid drug development platform includes a nucleic acid drug intelligent design NDDS (Novel Drug Delivery Systems) system, a mature delivery system, a complete drug evaluation platform and a polymer based multi-dose formulation platform.
The products are used in the field of anti-virus, anti-fibrosis and cardiovascular disease.
Current Investors
Hangzhou Miyin Investment Management, Chongqing Boyi Equity Investment Fund Management, Ze Long Investment Management Co.,Ltd
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.